INDICATION
RUKOBIA, in combination with other antiretrovirals (ARVs), is indicated to treat HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current ARV regimen due to resistance, intolerance, or safety considerations.



*Prevents HIV-1 from interacting with host immune cells by binding gp120, leaving CD4+ T-cells untouched.

Based on BRIGHTE 240-week data.

HIV-1=human immunodeficiency virus type-1;  gp120=glycoprotein 120.

RUKOBIA, as part of an optimized antiretroviral regimen,
is the only antiretroviral therapy specifically developed for people
living with multidrug-resistant HIV-1 clinically proven to offer
virologic suppression and
CD4+ T-cell recovery through ~5 years.
RUKOBIA, as part of an optimized antiretroviral regimen,
is the only antiretroviral therapy specifically developed for people
living with multidrug-resistant HIV-1 clinically proven to offer
virologic suppression and
CD4+ T-cell recovery through ~5 years.
The primary endpoint was the adjusted mean decline in HIV-1 RNA at Day 8: 0.79 log​ 10 copies/mL (RUKOBIA 600-mg BID + failing regimen, n=201) vs 0.17 log​ 10 copies/mL (placebo + failing regimen, n=69); difference: -0.625 (95% CI: -0.810, -0.441); P<0.0001. At Week 240, 45% of participants in the Snapshot Analysis and 82% in the Observed Analysis were virologically suppressed vs 53% and 57% at Week 24. The mean increase in CD4​ + T-cell counts from baseline at Week 240 was 296 cells/mm​ 3. The most adverse reaction (all grades) observed in ≥2% or randomized participants was nausea (11%). 1,2

~5-Year Data is Here

Sign Up for our next webinar

Read more »
edge of yesterday sub hero image
edge of yesterday sub hero image

Listen to Edge of Yesterday:

A Podcast Series by ViiV Healthcare

Read more »

"My name is James. I’m a heavily treatment-experienced person living with HIV. I have a great deal of hopefulness. I just have to remain positive.”

James, living with HIV.

Compensated by ViiV Healthcare.

DISCOVER RUKOBIA

BRIGHTE CLINICAL
TRIAL

Learn about the efficacy and safety of RUKOBIA in BRIGHTE

Read more »
pill icon

DOSING AND DRUG
INTERACTIONS

Learn about administering RUKOBIA

Read more »

ViiV MEDICAL
INFORMATION

View our medical information library if you have a question about RUKOBIA

Read more »

A DEEPER LOOK AT RUKOBIA

RISKS & SIDE EFFECTS

Get information about the possible risks and side effects, including warnings and precautions and rates of discontinuation

Read more »
MOA

A NOVEL
MECHANISM
OF ACTION

Learn what makes RUKOBIA a first-in-class HIV-1 attachment inhibitor1,2

Read more »

EDUCATIONAL RESOURCES

View educational library for RUKOBIA, including videos and a downloadable resource

Read more »

References:

  1. Ackerman P, Thompson M, Molina J M, et al. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. AIDS. 2021;35(7):1061-1072.
  2. Lataillade M, Lalezari JP, Kozal M, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2020;7(11):7 40-751.

FSTWCNT220020